(MENAFNEditorial) STARTRK-2
clinical trial sites in Asia working with Ignyta, Inc., (NASDAQ: RXDX), a biotechnology company focused on precision medicine in
oncology. Angsana Molecular & Diagnostics' RNA-based fusions cancer
panel will be used for screening TRK, ROS1 and ALK fusions in the STARTRK-2 clinical trial, a registration-enabling global Phase 2 basket clinical trial for
entrectinib, Ignyta's investigational, orally available, CNS-active tyrosine
kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions.
Phase 1 data recently published online in Cancer Discovery showed entrectinib to
be well tolerated, with responses observed in non-small cell lung cancer
(NSCLC), colorectal cancer, mammary analog secretory carcinoma (MASC), melanoma
and renal cell carcinoma as early as four weeks after first treatment and
lasting as long as 2.5 years and still ongoing. That
publication reported a 79% response rate in 24 patients with TRK, ROS1, or
ALK-driven extracranial solid tumors, and showed entrectinib responses to be
both rapid and durable in patients with advanced solid tumors across multiple
histologies and each of the molecular targets of interest, including in
multiple patients with metastatic CNS disease.
"Ignyta is excited to partner with Angsana to
conduct diagnostic screening at our STARTRK-2 clinical trial sites in Asia,
which will help us get entrectinib to patients with tumors driven by TRK, ROS1
or ALK fusions," said Jonathan Lim, M.D., Chairman and CEO of Ignyta.
"Entrectinib is the only TRK inhibitor to have published data
demonstrating RECIST responses in NSCLC and in patients with cancer in the CNS.
The anti-tumor activity seen across cancer types and entrectinib's ability to
treat bulky CNS disease, particularly important given the propensity for many
solid tumors to metastasize to the brain, is extremely encouraging," continued
Dr. Lim.
"The era of the shift away from
one-size-fits-all, trial-and-error medicine, toward a health care system that
utilizes molecular information to improve outcomes and make the health care
system more efficient, has finally arrived to Asia Pacific especially in the
area of targeted therapy for oncology,"says Dr. Chris Tan, Chief
Executive Officer and founder ofAngsana Molecular & Diagnostics.
Dr. Chris Tan added that our College of American Pathologists (CAP) accredited
molecular laboratories in Singapore and Hong Kong, turnaround time and cost
efficiency are critical to support Ignyta for their STARTRK-2 trial in
Singapore and Asia.
About Angsana Molecular & Diagnostics
Laboratory Angsana
Molecular & Diagnostics Laboratory specializes in developing premium
molecular diagnostic assays, serving the following four medical areas that have
the largest impact in Asian population: allergy and molecular allergology,
fetal maternal health, molecular oncology and pharmacogenetics. Through
analysis of medical conditions at a molecular level, combined with clinical
consultation by board-certified medical geneticists and sub-specialty trained
pathologists, Angsana empowers clinicians and patients to make better informed
clinical decisions and improve the quality of patient care. Strategically
located in the center of Asia with multi-laboratory CAP accredited operations
in Singapore and Hong Kong. Angsana Molecular & Diagnostics Laboratory is
dedicated to serving the Asian community with fast and more affordable services
within easy reach. For more information, visit www.angsanadx.com.
AboutIgnyta, Inc.
Blazing a New Future for Patients with Cancer™
At Ignyta, we work tirelessly on behalf of
patients with cancer to offer potentially life-saving, precisely targeted
therapeutics (Rx) guided by companion diagnostic (Dx) tests. Our integrated
Rx/Dx strategy allows us to enter uncharted territory, illuminating the
molecular drivers of cancer and quickly advancing treatments to address them.
This approach embraces even those patients with the rarest cancers, who have
the highest unmet need and who may otherwise not have access to effective
treatment options. With our pipeline of potentially first-in-class or
best-in-class precision medicines, we are pursuing the ultimate goal of not
just shrinking tumors, but eradicating cancer relapse and recurrence in
precisely defined patient populations.
For more information, please visit:
www.ignyta.com.
MENAFN1503201700703245ID1095315570
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.